Tags

Type your tag names separated by a space and hit enter

Calcitonin gene-related peptide antagonism and cluster headache: an emerging new treatment.
Neurol Sci. 2017 Dec; 38(12):2089-2093.NS

Abstract

Calcitonin gene-related peptide (CGRP) is a key signaling molecule involved in migraine pathophysiology. Efficacy of CGRP monoclonal antibodies and antagonists in migraine treatment has fueled an increasing interest in the prospect of treating cluster headache (CH) with CGRP antagonism. The exact role of CGRP and its mechanism of action in CH have not been fully clarified. A search for original studies and randomized controlled trials (RCTs) published in English was performed in PubMed and in ClinicalTrials.gov . The search term used was "cluster headache and calcitonin gene related peptide" and "primary headaches and calcitonin gene related peptide." Reference lists of identified articles were also searched for additional relevant papers. Human experimental studies have reported elevated plasma CGRP levels during both spontaneous and glyceryl trinitrate-induced cluster attacks. CGRP may play an important role in cluster headache pathophysiology. More refined human studies are warranted with regard to assay validation and using larger sample sizes. The results from RCTs may reveal the therapeutic potential of CGRP monoclonal antibodies and antagonists for cluster headache treatment.

Authors+Show Affiliations

Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.Department of Neurology, New York University School of Medicine, NYU Langone Medical Center, 240 East 38th Street, 20th Floor, New York, NY, 10016, USA.Department of Neurology, New York University School of Medicine, NYU Langone Medical Center, 240 East 38th Street, 20th Floor, New York, NY, 10016, USA. sait.ashina@nyumc.org.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28856479

Citation

Ashina, Håkan, et al. "Calcitonin Gene-related Peptide Antagonism and Cluster Headache: an Emerging New Treatment." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 38, no. 12, 2017, pp. 2089-2093.
Ashina H, Newman L, Ashina S. Calcitonin gene-related peptide antagonism and cluster headache: an emerging new treatment. Neurol Sci. 2017;38(12):2089-2093.
Ashina, H., Newman, L., & Ashina, S. (2017). Calcitonin gene-related peptide antagonism and cluster headache: an emerging new treatment. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 38(12), 2089-2093. https://doi.org/10.1007/s10072-017-3101-8
Ashina H, Newman L, Ashina S. Calcitonin Gene-related Peptide Antagonism and Cluster Headache: an Emerging New Treatment. Neurol Sci. 2017;38(12):2089-2093. PubMed PMID: 28856479.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Calcitonin gene-related peptide antagonism and cluster headache: an emerging new treatment. AU - Ashina,Håkan, AU - Newman,Lawrence, AU - Ashina,Sait, Y1 - 2017/08/30/ PY - 2017/06/04/received PY - 2017/08/22/accepted PY - 2017/9/1/pubmed PY - 2018/8/8/medline PY - 2017/9/1/entrez KW - Antagonism KW - Calcitonin gene-related peptide KW - Cluster headache KW - Pain KW - Pathophysiology KW - Trigeminal system SP - 2089 EP - 2093 JF - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JO - Neurol Sci VL - 38 IS - 12 N2 - Calcitonin gene-related peptide (CGRP) is a key signaling molecule involved in migraine pathophysiology. Efficacy of CGRP monoclonal antibodies and antagonists in migraine treatment has fueled an increasing interest in the prospect of treating cluster headache (CH) with CGRP antagonism. The exact role of CGRP and its mechanism of action in CH have not been fully clarified. A search for original studies and randomized controlled trials (RCTs) published in English was performed in PubMed and in ClinicalTrials.gov . The search term used was "cluster headache and calcitonin gene related peptide" and "primary headaches and calcitonin gene related peptide." Reference lists of identified articles were also searched for additional relevant papers. Human experimental studies have reported elevated plasma CGRP levels during both spontaneous and glyceryl trinitrate-induced cluster attacks. CGRP may play an important role in cluster headache pathophysiology. More refined human studies are warranted with regard to assay validation and using larger sample sizes. The results from RCTs may reveal the therapeutic potential of CGRP monoclonal antibodies and antagonists for cluster headache treatment. SN - 1590-3478 UR - https://www.unboundmedicine.com/medline/citation/28856479/Calcitonin_gene_related_peptide_antagonism_and_cluster_headache:_an_emerging_new_treatment_ L2 - https://link.springer.com/10.1007/s10072-017-3101-8 DB - PRIME DP - Unbound Medicine ER -